Sotatercept, a novel transforming growth factor β ligand trap, improves anemia in β-thalassemia: a phase II, open-label, dose-finding study
Maria Domenica Cappellini, John Porter, Raffaella Origa, Gian Luca Forni, Ersi Voskaridou, Frédéric Galactéros, Ali T Taher, Jean-Benoît Arlet, Jean-Antoine Ribeil, Maciej Garbowski, Giovanna Graziadei, Chantal Brouzes, Michaela Semeraro, Abderrahmane Laadem, Dimana Miteva, Jun Zou, Victoria Sung, Tatiana Zinger, Kenneth M Attie, Olivier Hermine, Maria Domenica Cappellini, John Porter, Raffaella Origa, Gian Luca Forni, Ersi Voskaridou, Frédéric Galactéros, Ali T Taher, Jean-Benoît Arlet, Jean-Antoine Ribeil, Maciej Garbowski, Giovanna Graziadei, Chantal Brouzes, Michaela Semeraro, Abderrahmane Laadem, Dimana Miteva, Jun Zou, Victoria Sung, Tatiana Zinger, Kenneth M Attie, Olivier Hermine
Abstract
β-thalassemia, a hereditary blood disorder caused by defective synthesis of hemoglobin β globin chains, leads to ineffective erythropoiesis and chronic anemia that may require blood transfusions. Sotatercept (ACE-011) acts as a ligand trap to inhibit negative regulators of late-stage erythropoiesis in the transforming growth factor β superfamily, correcting ineffective erythropoiesis. In this phase II, open-label, dose-finding study, 16 patients with transfusion-dependent β -thalassemia and 30 patients with non-transfusion-dependent β-thalassemia were enrolled at seven centers in four countries between November 2012 and November 2014. Patients were treated with sotatercept at doses of 0.1, 0.3, 0.5, 0.75, or 1.0 mg/kg to determine a safe and effective dose. Doses were administered by subcutaneous injection every 3 weeks. Patients were treated for ≤22 months. Response was assessed as a ≥20% reduction in transfusion burden sustained for 24 weeks in transfusion-dependent β-thalassemia patients, and an increase in hemoglobin level of ≥1.0 g/dL sustained for 12 weeks in non-transfusion-dependent β-thalassemia patients. Sotatercept was well tolerated. After a median treatment duration of 14.4 months (range 0.6-35.9), no severe life-threatening adverse events were observed. Thirteen percent of patients reported serious but manageable adverse events. The active dose of sotatercept was ≥0.3 mg/kg for patients with non-transfusion-dependent β-thalassemia and ≥0.5 mg/kg for those with transfusion-dependent β-thalassemia. Of 30 non-transfusion-dependent β-thalassemia patients treated with ≥0.1 mg/kg sotatercept, 18 (60%) achieved a mean hemoglobin increase ≥1.0 g/dL, and 11 (37%) an increase ≥1.5 g/dL, sustained for ≥12 weeks. Four (100%) transfusion-dependent β-thalassemia patients treated with 1.0 mg/kg sotatercept achieved a transfusion-burden reduction of ≥20%. Sotatercept was effective and well tolerated in patients with β-thalassemia. Most patients with non-transfusion-dependent β-thalassemia treated with higher doses achieved sustained increases in hemoglobin level. Transfusion-dependent β-thalassemia patients treated with higher doses of sotatercept achieved notable reductions in transfusion requirements. This trial was registered at ClinicalTrials.gov with the number NCT01571635.
Copyright© 2019 Ferrata Storti Foundation.
Figures
References
- Galanello R, Origa R. Beta-thalassemia. Orphanet J Rare Dis. 2010;5:11.
- Malamos B, Belcher EH, Gyftaki E, Binopoulos D. Simultaneous studies with Fe59 and Cr51 in congenital haemolytic anaemias. Nucl Med (Stuttg). 1961;2:1–20.
- Weatherall DJ, Clegg JB. The Thalassemia Syndromes. 2nd ed. Oxford, England: Blackwell Scientific Publications; 1972.
- Arlet JB, Dussiot M, Moura IC, Hermine O, Courtois G. Novel players in β-thalassemia dyserythropoiesis and new therapeutic strategies. Curr Opin Hematol. 2016;23(3): 181–188.
- Rund D, Rachmilewitz E. Beta-thalassemia. N Engl J Med. 2005;353(11):1135–1146.
- Melchiori L, Gardenghi S, Rivella S. Beta-thalassemia: HiJAKing ineffective erythropoiesis and iron overload. Adv Hematol, 2010;2010:938640.
- Fibach E, Rachmilewitz EA. Does erythropoietin have a role in the treatment of β- hemoglobinopathies? Hematol Oncol Clin North Am. 2014;28(2):249–263.
- Gardenghi S, Grady RW, Rivella S. Anemia, ineffective erythropoiesis, and hepcidin: interacting factors in abnormal iron metabolism leading to iron overload in β-thalassemia. Hematol Oncol Clin North Am. 2010;24(6):1089–1107.
- Cappellini MD, Cohen A, Porter J, Taher A, Viprakasit V. Guidelines for the Management of TD Thalassemia (TDT). 3rd ed. Nicosia, Cyprus: Thalassemia International Federation; 2014.
- Rund D. Thalassemia 2016: modern medicine battles an ancient disease. Am J Hematol. 2016;91(1):15–21.
- Haghpanah S, Nasirabadi S, Ghaffarpasand F, et al. Quality of life among Iranian patients with beta-thalassemia major using the SF-36 questionnaire. Sao Paulo Med J. 2013;131(3):166–172.
- Dahlui M, Hishamshah MI, Rahman AJ, Aljunid SM. Quality of life in transfusion-dependent thalassemia patients on desferrioxamine treatment. Singapore Med J. 2009;50(8):794–799.
- Baronciani D, Angelucci E, Potschger U, et al. Hematopoietic stem cell transplantation in thalassemia: a report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry, 2000–2010. Bone Marrow Transplant. 2016;51(4):536–541.
- Qari MH, Wali Y, Albagshi MH, et al. Regional consensus opinion for the management of beta thalassemia major in the Arabian Gulf area. Orphanet J Rare Dis. 2013;8:143.
- Angelucci E, Matthes-Martin S, Baronciani D, et al. Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel. Haematologica. 2014;99(5): 811–820.
- Negre O, Eggimann AV, Beuzard Y, et al. Gene therapy of the β-hemoglobinopathies by lentiviral transfer of the β(A(T87Q))-globin gene. Hum Gene Ther. 2016;27(2):148–165.
- Saliba AN, Taher AT. Morbidities in non-transfusion-dependent thalassemia. Ann N Y Acad Sci. 2016;1368(1):82–94.
- Taher A, Vichinsky E, Musallam K, Cappellini MD, Viprakasit V. Blood transfusion. In: Weatherall D, ed. Guidelines for the Management of Non Transfusion Dependent Thalassaemia (NTDT). Nicosia, Cyprus: Thalassaemia International Federation; 2013.
- Rachmilewitz EA, Giardina PJ. How I treat thalassemia. Blood. 2011;118(13):3479–3488.
- Carrancio S, Markovics J, Wong P, et al. An activin receptor IIA ligand trap promotes erythropoiesis resulting in a rapid induction of red blood cells and haemoglobin. Br J Haematol. 2014;165(6):870–882.
- Dussiot M, Maciel TT, Fricot A, et al. An activin receptor IIA ligand trap corrects ineffective erythropoiesis in β-thalassemia. Nat Med. 2014;20(4):398–407.
- Ruckle J, Jacobs M, Kramer W, et al. Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women. J Bone Miner Res. 2009;24(4):744–752.
- Komrokji R, Garcia-Manero G, Ades L, et al. Sotatercept with long-term extension for the treatment of anemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial. Lancet Haematol. 2018;5(2):e63–e72.
- Porter J, Garbowski M. Novel erythropoiesis stimulating agents in thalassemia. European Hematology Association Education Programme. 2015;9:311–320.
- Taher AT, Musallam KM, Karimi M, et al. Overview on practices in thalassemia inter-media management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood. 2010;115(10):1886–1892.
- Suragani RN, Cadena SM, Cawley SM, et al. Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. Nat Med. 2014;20(4):408–414.
- Platzbecker U, Germing U, Götze KS, et al. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label, phase 2 dose-finding study with long-term extension study. Lancet Oncol. 2017;18(10):1338–1347.
- Attie KM, Allison MJ, McClure T, et al. A phase 1 study of ACE-536, a regulator of erythroid differentiation, in healthy volunteers. Am J Hematol. 2014;89(7):766–770.
Source: PubMed